CD4 and neoplasm: Interestingly, while tumor tissue TCF1+ CD4 T cells were associated with a favorable response, as previously reported (Peng et al., 2021; Rong et al., 2022; Sade-Feldman et al., 2018), a high abundance of these cells (and TCF1+ CD8+ T cells) circulating in the bloodstream prior to treatment was unfavorable.